Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Nabi Biopharmaceuticals

1967 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
7 FINANCING ROUNDS
Description

Developer of vaccine products created for the treatment of nicotine addiction and prevention of smoking relapse. The company's innovative and proprietary clinical development programs are focused on powering the immune system in order to target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections.

Website
Formerly Known As
North American Biologicals
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 12270 Wilkins Avenue
  • Rockville, MD 20852
  • United States

Nabi Biopharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Nabi Biopharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Nabi Biopharmaceuticals Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Nabi Biopharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Nabi Biopharmaceuticals Executive Team (2)

Name Title Board
Seat
Contact
Info
Raafat Fahim Ph.D President & Chief Executive Officer

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »